Home › Funds › Vivo Capital, LLC › SVA

Vivo Capital, LLC position in SVA

Sinovac Biotech Ltd.

Vivo Capital, LLC reported holding 5,903,000 shares of SVA (Sinovac Biotech Ltd.) in its Q2 2026 13F filing — a position valued at US$38.2M, representing 3.49% of its reported portfolio and ranking #9 among its reported holdings. Vivo Capital, LLC has disclosed SVA holdings in 9 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)5.90M sh
Reported value held$38.19M
Portfolio Weight3.49%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Vivo Capital, LLC's SVA position evolved

Vivo Capital, LLC first disclosed a stake in SVA in Q3 2023 at 5,900,000 shares (US$38.2M). The position peaked in Q1 2024 at 11,800,000 shares, worth US$76.3M. Across 9 filings, Vivo Capital, LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 5,903,000 shares valued at US$38.2M.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 5.90M $38.17M New
Q1 2024 11.80M $76.35M New
Q2 2024 11.80M $76.35M Hold
Q3 2024 11.80M $76.35M Hold
Q2 2025 5.90M $38.19M New
Q3 2025 5.90M $38.19M Hold
Q4 2025 5.90M $38.19M Hold
Q1 2026 5.90M $38.19M Hold
Q2 2026 5.90M $38.19M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SVA and 13F data

SVA (Sinovac Biotech Ltd.) is a company whose sector is not yet classified in our data. 8 other funds we track also report a position in SVA — the largest reported positions include ORBIMED ADVISORS LLC (US$184.5M), Neumann Advisory Hong Kong Ltd (US$2.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SVA

All SVA fund holders →

FAQ

How long has Vivo Capital, LLC held SVA?

Vivo Capital, LLC has disclosed SVA holdings in 9 of the last 12 reported quarters, going back to Q3 2023.

What is Vivo Capital, LLC's current position in SVA?

As of Q2 2026, Vivo Capital, LLC holds 5.90M shares of SVA (Sinovac Biotech Ltd.), valued at $38.19M, representing 3.49% of its reported portfolio and ranking #9.

Has Vivo Capital, LLC been buying or selling SVA?

In the latest 13F filing (Q2 2026), Vivo Capital, LLC held unchanged its position in SVA. The position peaked in Q1 2024 at 11.80M shares.

Which other funds hold SVA?

Other major institutional holders of SVA include ORBIMED ADVISORS LLC, Neumann Advisory Hong Kong Ltd, among 8 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.